首页|University of Lorraine Reports Findings in Gliomas (Application of PET imaging delta radiomics for predicting progression-free survival in rare high-grade glioma)
University of Lorraine Reports Findings in Gliomas (Application of PET imaging delta radiomics for predicting progression-free survival in rare high-grade glioma)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
New research on Oncology - Gliomas is the subject of a report. According to news reporting originating from Nancy, France, by NewsRx correspondents, research stated, "This study assesses the feasibility of using a sample-efficient model to investigate radiomics changes over time for predicting progression-free survival in rare diseases. Eighteen high-grade glioma patients underwent two L-3,4-dihydroxy-6-[F]-fluoro-phenylalanine positron emission tomography (PET) dynamic scans: the first during treatment and the second at temozolomide chemotherapy discontinuation." Our news editors obtained a quote from the research from the University of Lorraine, "Radiomics features from static/dynamic parametric images, alongside conventional features, were extracted. After excluding highly correlated features, 16 different models were trained by combining various feature selection methods and time-to-event survival algorithms. Performance was assessed using cross-validation. To evaluate model robustness, an additional dataset including 35 patients with a single PET scan at therapy discontinuation was used. Model performance was compared with a strategy extracting informative features from the set of 35 patients and applying them to the 18 patients with 2 PET scans. Delta-absolute radiomics achieved the highest performance when the pipeline was directly applied to the 18-patient subset (support vector machine (SVM) and recursive feature elimination (RFE): C-index = 0.783 [0.744-0.818]). This result remained consistent when transferring informative features from 35 patients (SVM + RFE: C-index = 0.751 [0.716-0.784], p = 0.06)."
NancyFranceEuropeGliomasHealth and MedicineOncology
NETL
NSTL
